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We evaluated the individual and combined levels of urine dipstick and total lymphocyte count (TLC) as surrogate markers
for CD4 count in a low-resource community in Ghana. This cross-sectional study recruited 200 HIV-infected patients from
the Saint Francis Xavier Hospital, Assin Fosu, Ghana. Complete blood count, CD4 count, and urine dipstick analysis were
measured for participants. The threshold values were determined as <350 cells/μl for CD4, <1200 cells/μl for TLC, and
≥+ on urine dipstick analysis. The mean age of participants was 43.09 years. Proteinuria≥+ [aOR= 4.30 (3.0–18.5)],
leukocyturia≥+ [aOR= 2.91 (1.33–12.5)], hematuria ≥+ [aOR= 2.30 (1.08–9.64)], and TLC< 1200 cells/μl [aOR= 3.26
(3.94–15.29)] were significantly associated with increased risk of CD4 count< 350 cells/μl. Using the individual markers,
the best substitute marker for predicting CD4 count< 350 cells/μl was proteinuria at a cutoff point≥ 2++, AUC of 0.973,
sensitivity of 97.6%, specificity of 100.0%, PPV of 100.0%, and NPV of 89.1%. A combination of≤ 1200 TLC+≥ 2++
(leukocyturia + proteinuria + hematuria) yielded an AUC of 0.980, sensitivity (72.8%), specificity (100.0%), PPV (100.0%), and
NPV (97.9%). Proteinuria could serve as a noninvasive screening tool, but the combination of proteinuria, leukocyturia,
hematuria, and TLC serves as a better substitute marker for CD4 count in monitoring the disease progression among HIV
patients in low-resource communities.
1. Background
Human immunodeficiency virus (HIV) remains a public
health burden in both developed and underdeveloped
countries [1]. Globally, 37 million people are living with
HIV, out of which about 26 million of them reside in
sub-Saharan Africa [2]. In Ghana, the prevalence of HIV
among adult aged 15–49 years old has declined from
about 2.4% in 2013 to about 1.6% in 2015 [3]. The rapid
use of highly active antiretroviral therapy (HAART) in
the last eight years especially in developing countries has
yielded tremendous achievements and improvement of
CD4 counts of immune compromised individuals. The
previous guidelines recommended to start HAART for
HIV confirmed individuals with CD4 count< 200 cells/μl.
The current improvements in diagnosis and treatments
have led to the development of a new treatment guideline
which recommends HAART for all confirmed HIV
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individual with CD4 count 350 cells/μl to 500 cells/μl
depending on the clinical conditions and comorbidities
[4, 5]. Despite this achievement to treatment, most devel-
oping countries have inadequate facilities, inadequate
CD4 FASC count machines, inadequate human resources,
and insufficient supply of CD4 count reagents [6]. In
addition to the aforementioned challenges, Ghana still
faces a huge financial crisis needed to support HIV treat-
ment and repair broken-down FASC count machine [7].
For the reason that Ghana has not yet implemented the
latest WHO guidelines, means implementing it is likely
to increase enrolment of participants for HAART and
also worsen the challenges faced by the low-resource
communities [8].
The WHO recommendation that ART should com-
mence for all HIV-confirmed individuals in clinical stages
II or III with total lymphocyte count (TLC)< 1200 cell/μl
was also in recognition to the challenges faced by low-
resourced communities [9]. Following this initiation, some
studies have found a significant correlation between CD4
count and TLC [10–12]. The use of TLC yielded a high sen-
sitivity and specificity in predicting CD4 count< 200 cell/μl
among HIV-confirmed patients living in Ghana [13] and
Ethiopia [14]. However, other studies by Daka et al. [12]
and Akinola et al. [15] found TLC as a poor diagnostic
marker and hence could not recommend it as a substitute
for CD4 count. To overcome this limitation, some studies
explored the diagnostic performance of TLC in combina-
tion with other less expensive parameters such as hemo-
globin, hematocrit, BMI, and erythrocyte sedimentation
rate (ESR) [11, 16]. These studies observed a better sensi-
tivity and specificity of the combined markers for predict-
ing CD4 count< 200 cell/μl compared to using the
individual markers alone. Although, most of the markers
used in the latter studies were less expensive, they
required adequate expertise and extensive electricity
power supply. Hence, there is a need to develop a much
lesser expensive marker as a substitute for CD4 count in
these settings [17].
Noninvasive markers of dipstick urine abnormality
findings such as proteinuria, leukocyturia, and hematuria
were found to be significantly associated with a declined
CD4 count [18]. To date, very few studies have attempted
to confirm this finding. Whether the diagnostic perfor-
mance of the dipstick urinalysis findings will be a useful
substitute marker for CD4 count in a low-resource setting
like Ghana is yet to be explored. Very little or no research
has been conducted in Ghana among HIV-infected
HAART naive individual after the implementation of the
latest WHO cutoff point to start HAART. It is against this
background that this study evaluated the individual and
combined markers of urine dipstick findings and TLC as
substitute markers for CD4 count< 350 cell/μl in Ghana.
Dipstick urinalysis is less expensive and will develop inno-
vative approach to diagnosis and treatments, which will
further facilitate implementation of the latest WHO treat-
ment guideline.
2. Materials and Methods
2.1. Study Design, Period, and Setting. This was a hospital-
based cross-sectional study carried out at the HIV Clinic
of Saint Francis Xavier Hospital, Assin Fosu, in the Cen-
tral Region of Ghana from August 2016 to May 2017. Saint
Francis Xavier Hospital, Assin Fosu, is the largest hospital
in the central region of Ghana with a 118 bed capacity and
is a major referral centre that provides health services to
patients from a catchment area population of 207,000 in
Ghana [19].
2.2. Study Participants. Two hundred (200) newly diagnosed
HIV-infected patients between the ages of 15–64 years at the
HIV Clinic at Saint Francis Xavier Hospital were randomly
selected for the study. Patients under antiretroviral therapy,
pregnant women, and those with other medical conditions
such as sickle cell disease, viral hepatitis B or C, diabetes mel-
litus, systemic lupus erythematosus, tuberculosis and acute
viral infections, joint inflammatory diseases, sign of urinary
tract infections were excluded from the study. Other signs
of active infections and conditions that may interfere with
urine dipstick analysis or kidney function test were also
excluded. A questionnaire was used to collect sociodemo-
graphic characteristics of the study participants. Other vital
information pertaining to the clinical history of all partici-
pants was obtained from the hospital’s data review records
for each patient.
2.3. Ethical Consideration. This study was approved by the
Committee on Human Research Publications and Ethics
(CHRPE) at the School of Medical Sciences, Kwame Nkru-
mah University of Science and Technology and the Ethical
Committee of the at Saint Francis Xavier Hospital. Participa-
tion was voluntary and written informed consent was
obtained from each participant. All information obtained
from participants were kept under strict confidentiality.
2.4. Blood Collection, Total Lymphocyte, and CD4 Counts. A
volume of 5mL of venous blood was taken from the subjects
via phlebotomy and transferred into vacutainer tubes with
ethylenediaminetetraacetic acid (EDTA). Samples from the
subjects were analysed within 2 to 4 hours of collection.
The EDTA blood sample was used for the measurement of
CD4 cell count and complete blood count (CBC). FBC was
analysed using a five-differential automated blood analyzer
(HORIBA Yumizen H500, Horiba Medical, Japan) and
CD4 T lymphocyte count was determined using the Becton
Dickinson (BD) FASCount system (Becton, Dickinson and
Company, CA, USA). The BD FASCount system uses flow
cytometry for the quantification of the CD4 T lymphocytes.
Total lymphocyte count was determined and expressed
in cells/μl as follows:
White blood cell WBC × 1000 × percentage lymphocyte expressed as decimals 1
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2.5. Urine Collection and Biochemical Analysis. About 10–20
millilitres of early morning midstream urine were collected
from each participant into a clean leak-proof container for
analysis. Dipstick urinalysis strips (Accu-Tell Ref ABT-
UM-A33) were used to detect the following parameters in
urine provided by the participants: protein, glucose, biliru-
bin, urobilinogen, ketones, blood, and leukocytes.
2.6. Statistical Analysis. The data collected was entered into
Microsoft Excel and analyzed with SPSS version 23. The basic
characteristics were presented as means and standard devia-
tions (SD) for continuous data and as frequencies for cate-
gorical data. Comparisons between male and female were
made using independent Student’s t-tests for continuous data
and chi-square tests for categorical data. Receiver operating
characteristic (ROC) curves were used to demonstrate the
individual and combined diagnostic performance of selected
urine dipstick biochemistry and TLC as alternative markers
for CD4 count. Sensitivity, specificity, and positive and
negative predictive values were reported. Logistic regres-
sion analysis adjusting for signs of active infections and
conditions that may interfere with urine dipstick analysis
was performed to predict urine dipstick biochemistry and
TLC associated with CD4 counts. The level of significance
was set at p < 0 05 for all statistical comparisons.
3. Results
The mean age of participants was 43.09 years, and the most
frequently represented age group was 35–44 years (34.0%).
There was no significant difference between the mean ages
of males and females. There were more female participants
(71.5%) than males (28.5%) and a higher proportion of the
participants were divorced (56.0%) (Table 1).
As shown in Table 2, the general prevalence of leukocy-
turia, proteinuria, and hematuria was 50.0%, 54.5%, and
51.5%, respectively. There was no significant difference in
proportion between males and females in terms of the
presence andabsenceof leukocyturia (p = 0 3105), proteinuria
(p = 0 8871), and hematuria (p = 0 2121). Additionally, no
significant differencewas observed betweenmales and females
in terms of the mean concentration of CD4 (p = 0 1109),
TLC (p = 0 4017), Hb (p = 0 1992), and WBC (p = 0 3629).
There was a significant association of CD4 count with
leukocyturia (p < 0 0001), proteinuria (p < 0 0001), hematu-
ria (p < 0 0001), and TLC (p < 0 0001). Individuals with pro-
teinuria (≥+), leukocyturia (≥+), hematuria (≥+), and TLC
(<1200 cells/μl) were significantly associated with 4.30 times,
2.91 times, 2.30 times, and 3.26 times increased risk of CD4
count< 350 cells/μl, respectively, (Table 3).
Using various threshold points, the best cutoff point
for leukocyturia was ≥2++ with sensitivity of 92.1%, spec-
ificity of 98.9%, positive predicted values (PPV) of 100.0%,
and negative predicted value (NPV) of 83.3% for predict-
ing CD4 count< 350 cells/μl. The best threshold point
for proteinuria was ≥2++ with sensitivity of 97.6%, speci-
ficity of 100.0%, PPV of 100.0%, and NPV of 89.1% for
predicting CD4 count<350 cells/μl. The best threshold
point for hematuria was ≥2++ with sensitivity of 92.7%,
specificity of 98.6%, PPV of 100.0%, and NPV of 83.7%
for predicting CD4 count< 350 cells/μl. TLC of <1200
was shown to have a sensitivity of 85.1%, specificity of
100.0%, PPV of 100.0%, and NPV of 88.9% for predicting
CD4 count< 350 cells/μl. The best area under the curve
(AUC) was identified for proteinuria≥ 2++ (AUC=0.973)
followed by TLC (AUC=0.940), hematuria (AUC=0.938),
and leukocyturia (AUC=0.901). The closeness of the AUC
for proteinuria to “1.0” makes it a better diagnostic tool for
predicting CD4< 350 cell/μl, hence making it a better alter-
native marker for CD4 count (Table 4).
As shown in Table 5, using the best threshold
points <1200 cell/μl for TLC, ≥2++ for proteinuria, ≥2++
for leukocyturia, and ≥2++ for hematuria, a sensitivity of
72.8%, specificity of 100.0%, PPV of 100.0%, and NPV of
97.9% was found to predict CD4 count <350 cells/μl among
HIV-infected participants.
A shown in Figure 1, a higher AUC of 0.980 was
observed for the combination of the significant threshold
point for TLC, proteinuria, leukocyturia, and hematuria
making the combined markers a perfect alternative marker
for CD4 count.
4. Discussion
This study evaluated the individual and combined diagnostic
performances of some selected measures of dipstick urinaly-
sis and total lymphocyte count as alternative markers for
CD4 count in low-resource communities in Ghana.
Based on our result, there was a significantly high propor-
tion of hematuria, proteinuria, and leukocyturia among HIV-
infected participants with a declined CD4 count. Significantly
high counts of proteinuria, leukocyturia, and hematuria
were independent risk factors for CD4 count< 350 cell/μl.
A cross-sectional study conducted by FolefackKaze et al.
[20] among HIV-infected patients in Cameroon found sig-
nificant associations of proteinuria, hematuria, and leuko-
cyturia with a declined CD4 count, which is consistent
with the findings in our study. The prevalence of protein-
uria observed in this present study was significantly higher
Table 1: General characteristics of study participants.
Characteristics Frequency Percentages
Age (year)
15–24 10 5.0
25–34 47 23.5
35–44 68 34.0
45–54 47 23.5
55–64 28 14.0
Gender
Male 57 28.5
Female 143 71.5
Marital status
Single 53 26.5
Married 35 17.5
Divorced 112 56.0
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compared to the other urine abnormalities. This is consis-
tent with previous reports that proteinuria is the leading
urinary abnormality associated with declined CD4 count
[20]. Therefore, renal insufficiency could be the underlining
cause of proteinuria arising from an advanced stage HIV
infection and a declined CD4 count [20–22]. Conversely,
some studies found no significant association between renal
failure and a decline in CD4 count under routine clinical
management [23]. There is no clear mechanism linking a
declined CD4 count to the presence of hematuria in HIV
infection; however, this could be attributed to unforeseen
cofounders [24, 25].
Table 2: Urine dipstick biochemistry and CD4, TLC, Hb, and WBC categorized by sex.
Characteristics Total (n = 200) Male (n = 57) Female (n = 143) X2, df p value
Mean ageb 43.09± 10.33 43.44± 9.9 42.74± 10.76 0.5315
Leucocytesa 3.580, 3 0.3105
Absent 100 (50.0%) 23 (40.3%) 77 (53.8%)
1+ 28 (28.0%) 9 (15.8%) 19 (13.3%)
2++ 48 (48.0%) 18 (31.6%) 30 (21.0%)
3+++ 24 (24.0%) 7 (12.3%) 17 (11.9%)
Leukocyturia 100 (50.0%) 34 (34.0%) 66 (66.0%)
Proteina 4.503, 3 0.2121
Absent 97 (48.5%) 27 (47.4%) 70 (48.9%)
1+ 27 (13.5%) 12 (21.1%) 15 (10.5%)
2++ 51 (25.5%) 13 (22.8%) 38 (26.6%)
3+++ 25 (12.5%) 5 (8.8%) 20 (14.0%)
Proteinuria 103 (51.5%) 30 (29.1%) 73 (70.9%)
Blooda 0.6404, 3 0.8871
Absent 91 (45.5%) 25 (43.9%) 66 (46.1%)
1+ 27 (13.5%) 9 (15.7%) 18 (12.6%)
2++ 57 (28.5%) 15 (26.3%) 42 (29.4%)
3+++ 25 (12.5%) 8 (14.0%) 17 (11.9%)
Hematuria 109 (54.5%) 32 (29.4%) 77 (70.6%)
Mean CD4 (cell/μl)b 302.32± 32.4 273.43± 26.8 331.21± 38.0 0.1109
Mean TLC (cell/μl)b 1166.59± 73.7 1121.83± 90.32 1211.36± 57.18 0.4017
Mean HB (g/dl)b 7.32± 1.64 7.12± 1.85 7.52± 1.43 0.1992
Mean WBC (×109)b 2.36± 0.47 2.318± 0.51 2.403± 0.44 0.3629
Values are presented as mean ± SD and frequency (percentages). TLC: total lymphocyte count; Hb: hemoglobin; WBC: white blood cell. aChi-square test;
bStudent’s t-test.
Table 3: Association of CD4 count with urine dipstick biochemical analysis and TLC.
Characteristics Total CD4 count staging CD4< 350 cells/μl p value
<350 ≥350 aOR (95%C1)
Leukocyturia
Absent 100 8 (9.9%) 92 (77.3%) Reference
Present (≥+) 100 73 (90.1%) 27 (22.7%) 2.91(1.33 to 12.5) <0.0001
Proteinuria
Absent 91 1 (1.2%) 90 (75.6%) Reference
Present (≥+) 109 80 (98.8%) 29 (24.4%) 4.30 (3.0 to 18.5) <0.0001
Hematuria
Absent 97 10 (12.3%) 87 (73.1%) Reference
Present (≥+) 103 71 (87.6%) 32 (26.9%) 2.30 (1.08 to 9.64) <0.0001
TLC (cells/μl) Reference
≤1200 107 69 (85.1%) 38 (31.9%) 3.26 (3.94 to 15.29) <0.0001
>1200 93 12 (14.8%) 81 (68.1%)
aOR: adjusted odds ratio for signs of active infections and conditions that may interfere with urine dipstick analysis.
4 Disease Markers
When TLC and the individual markers of dipstick urinal-
ysis were explored for predicting CD4 count< 350 cells/μl,
proteinuria (at a cutoff point≥ 2++) was observed as the
best substitute for CD4 count with sensitivity of 97.6%,
specificity of 100.0%, PPV of 100.0%, and NPV of 89.1%.
Moreover, proteinuria when compared to TLC in this study
was found to be the second-best substitute marker with a
sensitivity of 85.1%, specificity of 100.0%, PPV of 100.0%,
and NPV of 88.9% at a threshold value of <1200 cell/μl.
Our findings, which indicated that proteinuria, could serve
as a better substitute marker for CD4 count is novel and
first of its kind to be reported in a Ghanaian setting. In a
cross-sectional study by Atta et al. [26], proteinuria yielded
a sensitivity, specificity, and positive and negative predictive
values of 73%, 61%, 53%, and 79%, respectively, for HIV-
associated nephropathy. An increased proteinuria depicts
decrease in glomerular filtration threshold or renal failure.
This finding is also supported by the significant association
between increased proteinuria and a decreased CD4 count
observed in our current study. HIV-infected individuals
with proteinuria≥ 2++ were 4.30 times more likely to
report with CD4 count below 350cells/μl. Early diagnosis
of proteinuria among HIV-infected patients will aid early
detection of renal impairment, and this will form the basis
to start HAART. Initiation of HAART has been shown to
improve HIV-associated nephropathy [27].
In some studies, conducted by Obirikorang et al. [13]
and Wondimeneh et al. [14], TLC was found to be the
Table 4: Individual diagnostic performance of selected urine dipstick biochemistry and TLC as alternative markers for CD4 Count.
Markers Sensitivity Specificity PPV NPV AUC (p value)
Leukocyturia 0.901 (p < 0 0001)
≥1+ 90.1% 77.3% 92.0% 73.1%
≥2++ 92.1% 98.9% 100.0% 83.3%
≥3+++ 68.3% 97.9% 88.70% 80.5%
Proteinuria 0.973 (p < 0 0001)
≥1+ 87.6% 73.1% 89.7% 68.9%
≥2++ 97.6% 100.0% 100.0% 89.1%
≥3+++ 73.0% 100.0% 99.8% 88.7%
Hematuria 0.938 (p < 0 0001)
≥1+ 98.7% 75.6% 98.9% 73.4%
≥2++ 92.7% 98.6% 100.0% 83.7%
≥3+++ 89.8% 93.1% 91.0% 85.2%
TLC (cell/μl) 0.940 (p < 0 0001)
<800 76.3% 68.1% 82.9% 78.0%
<1000 80.2% 74.8% 97.6% 84.3%
<1200 85.1% 100.0% 100.0% 88.9%
<1400 79.5% 87.2% 94.3% 72.3%
Table 5: Combined diagnostic performance of urine dipstick biochemistry and TLC as alternative markers for CD4.
Markers Sensitivity Specificity PPV NPV AUC (p value)
≤1200 TLC+ leukocyturia≥ 2++ 76.2% 100.0% 100.0% 87.3% 0.937 (p < 0 0001)
≤1200 TLC+proteinuria≥ 2++ 88.1% 100.0% 100.0% 93.8% 0.978 (p < 0 0001)
≤1200 TLC+hematuria≥ 2++ 83.3% 100.0% 100.0% 89.2% 0.960 (p < 0 0001)
≤1200 TLC+≥2++ (Leu + Pro +Hem) 72.8% 100.0% 100.0% 97.9% 0.980 (p < 0 0001)
Leu: leukocyturia; Pro: proteinuria; Hem: hematuria.
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Figure 1: Receiver operating characteristic (ROC) curve for
combined TLC, proteinuria, leukocyturia, and hematuria marker
for predicting <350cells/μl.
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best substitute marker for predicting disease progression in
HIV treatment naïve individuals with CD4 count <200
cell/μl. In this study, TLC was found to be the second-
best substitute marker for predicting CD4< 350 cell/μl.
The disparity in findings could be attributed to the differ-
ent CD4 count cutoff used. The use of CD4 count <350
cell/μl is likely to enroll a majority of participants leading
to an increasing statistical power and sample size com-
pared to using CD4 count <200 cell/μl. However, a
cross-sectional study by Kamya et al. [28] found conflict-
ing reports. Kamya and colleagues observed a 100% PPV
but 32.0% NPV for TLC, which implied that TLC could
limit the detection of HIV patients who are symptomatic
with >1200 cell/μl. Meanwhile, a similar cross-sectional
study in Ghana by Obirikorang and Quaye [13] observed
a sensitivity of 72.2%, specificity of 100.0%, PPV of
100.0%, and NPV of 95.7% at cutoff point< 1200cell/μl
in predicting CD4 count< 200 cell/μl. TLC was observed
as a better substitute for CD4 count in their study.
This study developed a combined marker comprising
TLC, proteinuria, hematuria, and leukocyturia using the
best cutoff points, and this yielded a better diagnostic
accuracy (98.0%) and a good predictive performance
for identifying HIV patients with CD4 count< 350
cell/μl compared to the individual markers (Figure 1).
This finding is novel and has not been reported else-
where. The 98.0% diagnostic accuracy of the combined
markers implied that only 2% will not need HAART.
The significant associations of TLC, proteinuria, leukocy-
turia, and hematuria with CD4 count indicate that these
markers play a synergistic role in the pathophysiology of
HIV infections.
Although the findings of this study are novel, there
were some limitations. We were not able to measure urine
albumin-creatinine ratio to explain the significance of the
proteinuria and how it relates to HIV-associated nephrop-
athy (HIVAN). Despite our extensive effort to rule out
confounding factors which may interfere with some dip-
stick findings like proteinuria, leukocyturia, and hematuria,
there may be possible unforeseen confounders which were
not controlled. However, we are confident in our findings
and for the first time in Ghana, our study will be a base-
line for further probing.
5. Conclusion
This study observed that proteinuria could serve as a nonin-
vasive screening tool for predicting the severity of HIV infec-
tion. Meanwhile, a combination of total lymphocyte count,
leukocyturia, proteinuria, and hematuria levels could serve
as a substitute marker for CD4 count in resource-limited
communities. It is therefore incumbent on the clinician to
incorporate urine dipstick screening in routine HIV moni-
toring and management.
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